vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Gogo Inc. (GOGO). Click either name above to swap in a different company.
Gogo Inc. is the larger business by last-quarter revenue ($230.6M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -4.3%, a 17.7% gap on every dollar of revenue. On growth, Gogo Inc. posted the faster year-over-year revenue change (67.3% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-25.4M). Over the past eight quarters, Gogo Inc.'s revenue compounded faster (48.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Gogo Inc. is an American provider of in-flight broadband Internet service and other connectivity services for business aircraft, headquartered in Broomfield, Colorado. Through its Gogo LLC subsidiary, Gogo previously provided in-flight WiFi to 17 airlines until the Commercial Air business was sold to Intelsat for $400 million in December 2020. According to Gogo, over 2,500 commercial aircraft and 6,600 business aircraft have been equipped with its onboard Wi-Fi services. The company is the de...
AMPH vs GOGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $230.6M |
| Net Profit | $24.4M | $-10.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 6.2% |
| Net Margin | 13.3% | -4.3% |
| Revenue YoY | -1.8% | 67.3% |
| Net Profit YoY | -35.7% | 64.6% |
| EPS (diluted) | $0.51 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $230.6M | ||
| Q3 25 | $191.8M | $223.6M | ||
| Q2 25 | $174.4M | $226.0M | ||
| Q1 25 | $170.5M | $230.3M | ||
| Q4 24 | $186.5M | $137.8M | ||
| Q3 24 | $191.2M | $100.5M | ||
| Q2 24 | $182.4M | $102.1M | ||
| Q1 24 | $171.8M | $104.3M |
| Q4 25 | $24.4M | $-10.0M | ||
| Q3 25 | $17.4M | $-1.9M | ||
| Q2 25 | $31.0M | $12.8M | ||
| Q1 25 | $25.3M | $12.0M | ||
| Q4 24 | $38.0M | $-28.2M | ||
| Q3 24 | $40.4M | $10.6M | ||
| Q2 24 | $37.9M | $839.0K | ||
| Q1 24 | $43.2M | $30.5M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | 87.8% | ||
| Q1 25 | 50.0% | 87.3% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 6.2% | ||
| Q3 25 | 13.2% | 12.9% | ||
| Q2 25 | 24.2% | 15.9% | ||
| Q1 25 | 21.9% | 15.3% | ||
| Q4 24 | 24.2% | -17.5% | ||
| Q3 24 | 29.8% | 19.0% | ||
| Q2 24 | 30.3% | 21.2% | ||
| Q1 24 | 27.9% | 33.2% |
| Q4 25 | 13.3% | -4.3% | ||
| Q3 25 | 9.0% | -0.9% | ||
| Q2 25 | 17.8% | 5.7% | ||
| Q1 25 | 14.8% | 5.2% | ||
| Q4 24 | 20.4% | -20.5% | ||
| Q3 24 | 21.1% | 10.6% | ||
| Q2 24 | 20.8% | 0.8% | ||
| Q1 24 | 25.1% | 29.2% |
| Q4 25 | $0.51 | $-0.08 | ||
| Q3 25 | $0.37 | $-0.01 | ||
| Q2 25 | $0.64 | $0.09 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $-0.22 | ||
| Q3 24 | $0.78 | $0.08 | ||
| Q2 24 | $0.73 | $0.01 | ||
| Q1 24 | $0.81 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $125.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $101.1M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $125.2M | ||
| Q3 25 | $276.2M | $133.6M | ||
| Q2 25 | $231.8M | $102.1M | ||
| Q1 25 | $236.9M | $70.3M | ||
| Q4 24 | $221.6M | $41.8M | ||
| Q3 24 | $250.5M | $176.7M | ||
| Q2 24 | $217.8M | $161.6M | ||
| Q1 24 | $289.6M | $152.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $101.1M | ||
| Q3 25 | $776.7M | $107.0M | ||
| Q2 25 | $757.5M | $102.8M | ||
| Q1 25 | $751.3M | $82.9M | ||
| Q4 24 | $732.3M | $69.3M | ||
| Q3 24 | $727.7M | $52.7M | ||
| Q2 24 | $713.3M | $52.0M | ||
| Q1 24 | $672.4M | $62.4M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $810.7M | ||
| Q2 24 | $1.5B | $802.7M | ||
| Q1 24 | $1.6B | $809.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $8.5M |
| Free Cash FlowOCF − Capex | $24.6M | $-25.4M |
| FCF MarginFCF / Revenue | 13.4% | -11.0% |
| Capex IntensityCapex / Revenue | 4.5% | 14.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $65.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $8.5M | ||
| Q3 25 | $52.6M | $46.8M | ||
| Q2 25 | $35.6M | $36.7M | ||
| Q1 25 | $35.1M | $32.5M | ||
| Q4 24 | $29.0M | $-38.3M | ||
| Q3 24 | $60.0M | $25.1M | ||
| Q2 24 | $69.1M | $24.9M | ||
| Q1 24 | $55.3M | $29.7M |
| Q4 25 | $24.6M | $-25.4M | ||
| Q3 25 | $47.2M | $27.3M | ||
| Q2 25 | $25.0M | $33.5M | ||
| Q1 25 | $24.4M | $29.7M | ||
| Q4 24 | $16.6M | $-42.6M | ||
| Q3 24 | $46.2M | $20.7M | ||
| Q2 24 | $63.1M | $21.6M | ||
| Q1 24 | $46.5M | $28.2M |
| Q4 25 | 13.4% | -11.0% | ||
| Q3 25 | 24.6% | 12.2% | ||
| Q2 25 | 14.3% | 14.8% | ||
| Q1 25 | 14.3% | 12.9% | ||
| Q4 24 | 8.9% | -30.9% | ||
| Q3 24 | 24.1% | 20.6% | ||
| Q2 24 | 34.6% | 21.1% | ||
| Q1 24 | 27.1% | 27.0% |
| Q4 25 | 4.5% | 14.7% | ||
| Q3 25 | 2.8% | 8.7% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 1.2% | ||
| Q4 24 | 6.7% | 3.1% | ||
| Q3 24 | 7.2% | 4.4% | ||
| Q2 24 | 3.3% | 3.3% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 2.87× | ||
| Q1 25 | 1.39× | 2.70× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 2.36× | ||
| Q2 24 | 1.82× | 29.74× | ||
| Q1 24 | 1.28× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GOGO
| Services | $191.9M | 83% |
| Products | $38.7M | 17% |
| Fcc Reimbursement Program | $2.0M | 1% |
